Trial Profile
A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 Mar 2023 Status changed from active, no longer recruiting to completed, as per Japan Pharmaceutical Information Center record.
- 01 Mar 2023 Results of 1-year efficacy and safety data and biomarker analysis data regarding mechanisms of resistance to axi-cel, published in the International Journal of Hematology
- 16 Dec 2021 Results presented in a Daiichi Sankyo Company Media Release.